| Size | Price | |
|---|---|---|
| Other Sizes |
Purity: ≥98%
Kinetin (also called 6-Furfuryladenine; N6-Furfuryladenine) is a cytokinin compound and a class of plant hormone that promotes cell division. Kinetin is often used in plant tissue culture for inducing formation of callus (in conjunction with auxin) and to regenerate shoot tissues from callus. At present, kinetin is one of the widely used anti-aging agents in numerous skin care cosmetics and cosmeceuticals, such as Valeant products kinerase.
| ln Vitro |
Kinetin (N6-furfuryladenine) slows the development and aging of insects, delays the onset of many age-related characteristics seen in normal human skin fibroblasts aged in vitro, and has a direct effect on superoxide dismutase activity in plants. It also prevents the oxidation of unsaturated acids in plant membranes, reduces insect fecundity, and increases the specific activity of catalase. The production of hydroxyl radicals is greatly inhibited by kinetin (70-150 μM) by roughly 41% and 76%, respectively [1]. The cytokinin kinetin found in plants considerably raises the quantity of exon 20 in RNA extracted from cultivated familial dysautonomia (FD) cells [2].
|
|---|---|
| ln Vivo |
ADP-induced acute pulmonary thrombosis in mice can be successfully avoided by kinetin (N6-furfuryladenine) injections administered via tail vein (2–6 mg/kg) [1]. For 28 days, subjects were given a dosage of 23.5 mg/kg per day. Six out of eight people had increased WT IKBKAP mRNA expression in their leukocytes after eight days, and the mean increase was statistically significant when compared to the baseline after twenty-eight days [3].
|
| Animal Protocol |
Animal/Disease Models: ADP-induced acute pulmonary thrombosis 20-24 g mice (ICR strain) [1]
Doses: 2, 4, 6 mg/kg Route of Administration: Tail vein injection Experimental Results: Mortality diminished to 70%, 40 % and 35 are 2, 4 and 6 mg/kg respectively. |
| Toxicity/Toxicokinetics |
Interactions
The effects of a long-term (15 day) or short-term (3 or 15 h) treatment with 1 mM aluminium on peroxidase activity, lipid peroxidation and multiplication rate (15 day) were evaluated in Lemna minor L. Kinetin or citrate were administered together with Al in the culture medium in the long-term study or immediately after Al treatment in the short-term study, to mitigate Al toxicity. ... Increments in enzyme activity and lipid peroxidation and a decrease in multiplication rate were observed after Al treatments. Citrate was capable of lowering the Al-induced increase in peroxidase activity in the long- and short-term treatments. The large increase in lipid peroxidation induced by Al was blocked by kinetin and, to a lesser extent, by citrate; the latter more effectively limited the decrease in multiplication rate induced by Al. Non-Human Toxicity Values LD50 Rat oral >5 g/kg /Cytokinins/ LD50 Rabbit percutaneous >2 g/kg /Cytokinins/ LD50 Mouse ip 450 mg/kg |
| References |
|
| Additional Infomation |
Kinetin is a member of the class of 6-aminopurines that is adenine carrying a (furan-2-ylmethyl) substituent at the exocyclic amino group. It has a role as a geroprotector and a cytokinin. It is a member of furans and a member of 6-aminopurines.
Kinetin is a cytokinin which are plant hormones promotes cell division and plant growth. It was shown to naturally exist in DNA of organisms including humans and various plants. While kinetin is used in tissue cultures to produce new plants, it is also found in cosmetic products as an anti-aging agents. Kinetin has been reported in Humulus lupulus, Cocos nucifera, and other organisms with data available. A furanyl adenine found in PLANTS and FUNGI. It has plant growth regulation effects. |
| Molecular Formula |
C10H9N5O
|
|
|---|---|---|
| Molecular Weight |
215.21
|
|
| Exact Mass |
215.08
|
|
| Elemental Analysis |
C, 55.81; H, 4.22; N, 32.54; O, 7.43
|
|
| CAS # |
525-79-1
|
|
| Related CAS # |
|
|
| PubChem CID |
3830
|
|
| Appearance |
White to light yellow solid powder
|
|
| Density |
1.6±0.1 g/cm3
|
|
| Boiling Point |
367.6±52.0 °C at 760 mmHg
|
|
| Melting Point |
269-271 °C (dec.)(lit.)
|
|
| Flash Point |
176.1±30.7 °C
|
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
|
| Index of Refraction |
1.774
|
|
| LogP |
-0.56
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
16
|
|
| Complexity |
239
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O1C([H])=C([H])C([H])=C1C([H])([H])N([H])C1C2=C(N=C([H])N=1)N=C([H])N2[H]
|
|
| InChi Key |
QANMHLXAZMSUEX-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C10H9N5O/c1-2-7(16-3-1)4-11-9-8-10(13-5-12-8)15-6-14-9/h1-3,5-6H,4H2,(H2,11,12,13,14,15)
|
|
| Chemical Name |
N-(furan-2-ylmethyl)-7H-purin-6-amine
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.62 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.62 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6466 mL | 23.2331 mL | 46.4662 mL | |
| 5 mM | 0.9293 mL | 4.6466 mL | 9.2932 mL | |
| 10 mM | 0.4647 mL | 2.3233 mL | 4.6466 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01898182 | Completed | Other: Kinetin, N6- furfuryladenine, 0.1% |
Cutaneous Photoaging | Makati Medical Center | November 2013 | Phase 4 |
| NCT02274051 | Completed | Dietary Supplement: Kinetin | Familial Dysautonomia | NYU Langone Health | November 2009 | Phase 1 |
| NCT01885091 | Completed | Other: Kinerase | Skin Roughness Mottling Blotchiness |
Menarini (Thailand) Limited | December 2012 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA